Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

We are recommending Skye Bioscience Inc. (SKYE) as our next investment opportunity in treating metabolic disease/obesity. Skye is developing a peripheral restricted CB1 antibody — nimacimab — to treat ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

Discover how compounded semaglutide enhances the body's natural insulin function, aiding in blood sugar control and diabetes ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...